We Have One Goal: A World Without Blood Cancers


Today, The Leukemia & Lymphoma Society (LLS) is the world’s largest voluntary health agency dedicated to finding cures for leukemia, lymphoma, myeloma and other blood cancers. Thanks to research, survival rates for patients with many blood cancers have doubled, tripled and even quadrupled since the early 1960s.

Despite these advances, about one third of patients with a blood cancer still do not survive even five years after their diagnosis, which is why more funding is needed to bring better therapies to patients, and faster.

To date, LLS has invested more than $ 1 billion in research to advance therapies and save lives. LLS research grants have funded many of today’s most promising advances, including targeted therapies and immunotherapies. Sustained research investments are fueling an explosion of innovative science and clinical successes. New safe and effective treatments, once unimaginable, are saving lives today.

Research Support that Leads to Results

And, advances are far-reaching. From 2000 through 2013, almost 40 percent of new anti-cancer drugs were FDA-approved for blood cancer patients -- more first-ever approvals than for any other group of cancers -- and many of these were advanced with funding from LLS. Some therapies are even helping patients with other cancers and other serious, nonmalignant diseases.

LLS supports the world’s best and brightest academic researchers to address these urgent, unmet needs.

We provide funding across the continuum from basic and translational research through clinical trials, from bench to bedside.

Recognizing that therapies were not getting to patients fast enough, we created the Therapy Acceleration Program, supporting applied research and forging collaborations with biotechnology companies to help bridge the gap between academic discovery and successful drug development.

We are a catalyst for collaboration and we are leaders in venture philanthropy in oncology.

Help for People Touched by Blood Cancers

We are the leading source of free blood cancer information, education and support for patients, survivors, families and healthcare professionals. In North America, our co-pay assistance program has raised more than $200 million to date to help eligible blood cancer patients afford health-insurance premiums and prescription drug co-pays. The program has assisted more than 36,000 patients since its inception in 2007.

Our Information Resource Center provides the public, families, health professionals and people living with blood-related cancer with a wide variety of services and resources including accurate, up-to-date, disease-related information and referral services; teleconferences and educational webcasts; support groups; information on the latest clinical trials and treatments; workshops that address survivorship issues; and an award-winning website.

Since its inception in 1997, our Information Resource Center has interacted with more than one million callers.

Last year alone, LLS specialists fielded almost 60,000 inquiries and performed more than 6,000 clinical trial searches using the LLS’s TrialCheck tool.

LLS is the voice for all blood cancer patients and we are working to ensure that all blood cancer patients have access to the best available therapies. We touch patients and their families through our chapters across the United States and Canada. We advocate for policies at the federal and state levels to accelerate the approval of new treatments and ensure access to quality, affordable and coordinated care.

Continue Reading